Patents by Inventor Giulio M. Pasinetti

Giulio M. Pasinetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8921347
    Abstract: Methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis are provided. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. Also provided are methods of treating or preventing Alzheimer's disease or MCI that involve the use of such compositions. Also provided are methods of using D-pinitol to promote a healthy nervous system and as a food supplement.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: December 30, 2014
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventor: Giulio M. Pasinetti
  • Publication number: 20130123370
    Abstract: Methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis are provided. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. Also provided are methods of treating or preventing Alzheimer's disease or MCI that involve the use of such compositions. Also provided are methods of using D-pinitol to promote a healthy nervous system and as a food supplement.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 16, 2013
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE
    Inventor: Giulio M. Pasinetti
  • Patent number: 8193250
    Abstract: The present invention relates generally to methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. The invention also relates to methods of treating or preventing Alzheimer's disease or MCI that involve the use of such compositions. The invention further provides methods to promote the general health of the nervous system through administration of active ingredient compositions. The invention further relates to animal and cellular systems for the study of AD, MCI, and related disorders, and the identification of reagents useful in treating amyloidosis. The invention further provides methods to inhibit AD or MCI in an individual based on reducing caloric intake by the individual.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: June 5, 2012
    Assignee: Mount Sinai School of Medicine
    Inventor: Giulio M. Pasinetti
  • Patent number: 7226948
    Abstract: The present invention relates to the use of nimesulide and structurally related compounds in the prevention and/or treatment of neurodegenerative conditions. It is based, at least in part, on the discovery that nimesulide exhibits a neuroprotective effect against ?-amyloid induced cell death. Without being bound to any particular theory, it appears that nimesulide inhibits a non-inflammatory mechanism of neurodegeneration.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: June 5, 2007
    Assignee: University of Mount Sinai School of Medicine of the City of New York
    Inventors: Giulio M. Pasinetti, Paul S. Aisen
  • Patent number: 6649811
    Abstract: The invention provides for transgenic mice whose genomes comprise a gene encoding human cyclooxygenase-2 under the control of a neuron-specific promoter. The transgenic mice of the instant invention express human cyclooxygenase-2 mRNA in neuronal cells of their hippocampi at increased levels relative to the level of human cyclooxygenase-2 mRNA expressed in their cerebral white matter. Moreover, neuronal cell cultures derived from the transgenic mice of the instant invention arc more susceptible to aggregated A&bgr;25-35 peptide-mediated impairment of redox activity relative to those derived from mice non-transgenic for the human cyclooxygenase-2 gene. These transgenic animals and the neuronal cultures derived therefrom are useful iii elucidating the pathophysiological bases of neurodegenerative diseases and in improving the diagnosis and treatment of these disorders.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: November 18, 2003
    Assignee: Mount Sinai of Medicine of New York University
    Inventor: Giulio M. Pasinetti
  • Publication number: 20020162130
    Abstract: The present invention relates to the use of nimesulide and structurally related compounds in the prevention and/or treatment of neurodegenerative conditions. It is based, at least in part, on the discovery that nimesulide exhibits a neuroprotective effect against &bgr.
    Type: Application
    Filed: July 16, 1999
    Publication date: October 31, 2002
    Inventors: GIULIO M. PASINETTI, PAUL S. AISEN
  • Patent number: 5985930
    Abstract: The present invention relates to the use of nimesulide and structurally related compounds in the prevention and/or treatment of neurodegenerative conditions. It is based, at least in part, on the discovery that nimesulide exhibits a neuroprotective effect against .beta.-amyloid induced cell death. Without being bound to any particular theory, it appears that nimesulide inhibits a non-inflammatory mechanism of neurodegeneration.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: November 16, 1999
    Inventors: Giulio M. Pasinetti, Paul S. Aisen